Kalaris Therapeutics Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KLRS research report →
Range $14 – $17
Price Chart
About the company
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
- CEO
- Andrew Oxtoby
- IPO
- 2020
- Employees
- 20
- HQ
- Berkeley Heights, NJ, US
Get TickerSpark's AI analysis on KLRS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $58.06M
- P/E
- -1.32
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 1.10
- EV/EBITDA
- -0.36
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -71.71%
- ROIC
- -52.40%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-13,000+0.0%
- Op Income
- $-46,152,000
- Net Income
- $-43,438,000+26.1%
- EPS
- $-2.85+75.7%
- OCF Growth
- +36.5%
- FCF Growth
- +36.2%
- 52W High
- $11.88
- 52W Low
- $2.51
- 50D MA
- $3.62
- 200D MA
- $6.07
- Beta
- 0.21
- RSI (14)
- 26
- Avg Volume
- 253.62K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Alvarion reported a smaller continuing-business quarter as it narrows focus to unlicensed wireless, cuts costs, and prepares a reverse split to keep its NASDAQ listing.· March 4, 2013
- Q4 revenue from continuing operations was $8.2 million, with non-GAAP gross margin at 38.2% and a non-GAAP loss of $0.07 per share.
- Management said the DWA sale to Telrad is the right strategic move and that Alvarion will now focus on unlicensed solutions in vertical markets and carrier Wi-Fi.
- Cost reductions are showing up: quarterly expenses for the unlicensed business were about $7 million versus $9 million in Q1 2012, and Q1 2013 expenses are expected to stay similar to Q4 before declining slightly.
- Cash and balance sheet improved, with $40.4 million in cash, cash equivalents and investments at Dec. 31 and debt down to $11 million from $13 million at the start of the year.
- The company still faces a NASDAQ compliance deadline of April 22 and plans a reverse split of up to 1-for-10 around April 1, 2013.
In Q4, revenue was $8.2 million, down from $10.9 million in Q4 of the prior year. Non-GAAP gross margin was 38.2% versus 46.5% in Q3, and the decline was attributed mainly to lower revenue. GAAP operating expenses were $7.9 million; non-GAAP operating expenses were $7.1 million versus $7.6 million in Q3. GAAP net loss from continuing operations was $0.08 per share, non-GAAP net loss was $0.07 per share, and discontinued operations added a $0.19 per share net loss. Cash, cash equivalents and investments totaled $40.4 million at Dec. 31, and debt stood at $11 million versus $13 million at the beginning of the year. For Q1 2013, operating expenses were expected to remain similar to Q4 and then decline slightly in subsequent quarters; gross margin for the unlicensed business was expected to be around Q3 levels.
Hezi Lapid framed the quarter as a transition point, saying the sale of the carrier licensed division (DWA) to Telrad is the best outcome for shareholders and customers given market conditions and limited resources. He said the company will concentrate on unlicensed broadband where it sees the most growth potential, especially vertical markets and carrier Wi-Fi. His tone was cautious but constructive: he repeatedly acknowledged the company is not yet profitable, but said the turnaround plan is working and profitability is achievable.
Avi Stern focused on the financial cleanup and the narrower continuing business. He said Q4 continuing-business revenue was $8.2 million, non-GAAP operating expenses were $7.1 million, and non-GAAP gross margin was 38.2%; he also said gross margin should return to around Q3 levels. On liquidity and leverage, he said cash, cash equivalents and investments were $40.4 million at Dec. 31, the company made an additional $1 million principal repayment to Silicon Valley Bank in Q4, and debt was down to $11 million from $13 million at the start of the year. He also noted inventory at $9.3 million and DSOs at 115 days, up from 111 days.
Analysts pressed for more detail on the carrier Wi-Fi business, including whether 2012 came near an earlier $25 million target, but management declined to break out product-line revenue. Questions also focused on whether the $8 million revenue run rate was a floor and how the company could realistically return to break-even. Hezi Lapid said he would not give guidance, but if $8 million is not the low point he would be disappointed; he also said break-even is around $11.5 million in revenue with $6 million to $7 million in expenses, and that more disclosure would not likely fix the NASDAQ listing issue.
The bull case from the call is that Alvarion is simplifying its business and concentrating on the segments management believes have the best growth prospects. Cost cuts have lowered quarterly unlicensed-business expenses to about $7 million, cash is still healthy at $40.4 million, and management sees gross margin rebounding toward Q3 levels as volume improves. The company also highlighted new partnerships, product upgrades, and customer deployments in areas like mobile offload and industrial connectivity.
The bear case is that the company is still losing money and faces near-term listing risk, with an April 22 NASDAQ compliance deadline and a planned reverse split. Revenue fell year over year, gross margin dropped sharply in Q4, and management would not provide detailed revenue guidance or product-line disclosure. Analysts also pointed to uncertainty around the Wi-Fi business pace and whether current revenue is near a bottom or still vulnerable to further erosion.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 32.7%
- Shares Outstanding
- 21.83M
- Float Shares
- 7.14M
of shares held by institutions
58 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Samsara Biocapital, LLC | 12.88M | ▼ 66.91K |
| Rtw Investments, LP | 1.30M | 0 |
| Alyeska Investment Group, L.P. | 572.69K | 0 |
| Siren, L.L.C. | 435.80K | 0 |
| Vanguard Capital Management LLC | 398.71K | ▲ 143.36K |
| Ikarian Capital, LLC | 360.00K | 0 |
| Vanguard Group Inc | 292.79K | ▲ 89.74K |
| Ubs Group AG | 262.13K | ▲ 255.95K |
| Renaissance Technologies LLC | 149.35K | ▲ 83.20K |
| Marshall Wace, Llp | 139.20K | ▲ 71.32K |
| Geode Capital Management, LLC | 114.04K | ▲ 26.49K |
| Woodline Partners LP | 100.00K | 0 |
Held by 29 ETFs
Biggest fund positions in KLRS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 27, 26 | Vandekop Amy O'Leary | other | 10,000 |
| Aug 1, 26 | KEATING LAURIE | other | 18,000 |
| Aug 1, 26 | KEATING LAURIE | other | 0 |
| Jul 27, 26 | Vandekop Amy O'Leary | other | 0 |
| Jul 27, 26 | Vandekop Amy O'Leary | other | 27,415 |
| Jul 27, 26 | Vandekop Amy O'Leary | other | 20,000 |
| Jul 20, 26 | Bayko Liisa Ann | other | 220,000 |
| Jul 20, 26 | Bayko Liisa Ann | other | 0 |
| Jun 3, 26 | Jovan-Embiricos Morana | other | 9,000 |
| Jun 3, 26 | Ferrara Napoleone | other | 9,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KLRS coverage
Recent articles, reports, and earnings notes.
No research on KLRS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KLRS report →Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Price Target of $18.75
defenseworld.net · Sep 28
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
globenewswire.com · Aug 31
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Aug 11
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% – Here’s What Happened
defenseworld.net · Aug 4
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders
globenewswire.com · Aug 3
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
globenewswire.com · Jul 20
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
globenewswire.com · Jul 17
Kalaris Appoints Laurie Keating to Board of Directors
globenewswire.com · Jul 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.